The aim was to determine the release-modifying effect of carboxymethyl xyloglucan for oral drug delivery. Sustained release matrix tablets of tramadol HCl were prepared by wet granulation method using carboxymethyl xyloglucan as matrix forming polymer. HPMC K100M was used in a small amount to control the burst effect which is most commonly seen with natural hydrophilic polymers. A simplex centroid design with three independent variables and two dependent variables was employed to systematically optimize drug release profile. Carboxymethyl xyloglucan , HPMC K100M , and dicalcium phosphate were taken as independent variables. The dependent variables selected were percent of drug release at 2nd hour and at 8th hour . Response surface plots were developed, and optimum formulations were selected on the basis of desirability. The formulated tablets showed anomalous release mechanism and followed matrix drug release kinetics, resulting in regulated and complete release from the tablets within 8 to 10 hours. The polymer carboxymethyl xyloglucan and HPMC K100M had significant effect on drug release from the tablet ( ). Polynomial mathematical models, generated for various response variables using multiple regression analysis, were found to be statistically significant ( ). The statistical models developed for optimization were found to be valid. 1. Introduction Hydrophilic matrices are an interesting option while developing an oral sustained-release formulation. They can be used for controlled release of both water-soluble and water-insoluble drugs. The release behaviour of drugs varies with the nature of the matrix and it is the complex interaction of swelling, diffusion, and erosion processes [1]. Polysaccharides are the choice of material which has been evaluated as hydrophilic matrix for drug delivery system due to their nontoxicity and acceptance by regulating authorities. Xyloglucan is a natural polysaccharide isolated from seed kernel of Tamarindus indica. It is used as ingredient in food and pharmaceutical industry. It has been significantly evaluated for use in hydrophilic drug delivery system. It possesses high viscosity, broad pH tolerance, and swelling and binding properties [2]. This led to its application as release retardant polymer and binder in pharmaceutical industry. In addition to these, other important properties of xyloglucan have been identified recently, which include noncarcinogenicity [3], mucoadhesivity, biocompatibility [4], high drug holding capacity [5], and high thermal stability [6]. This led to its application as excipient in
References
[1]
P. Colombo, R. Bettini, G. Massimo, P. L. Catellani, P. Santi, and N. A. Peppas, “Drug diffusion front movement is important in drug release control from swellable matrix tablets,” Journal of Pharmaceutical Sciences, vol. 84, no. 8, pp. 991–997, 1995.
[2]
P. S. Rao, T. P. Ghosh, and S. Krishna, “Extraction and purification of tamarind seed polysaccharide,” Journal of Scientific & Industrial Research, vol. 4, article 705, 1946.
[3]
M. Sano, E. Miyata, S. Tamano, A. Hagiwara, N. Ito, and T. Shirai, “Lack of carcinogenicity of tamarind seed polysaccharide in B6C3F1 mice,” Food and Chemical Toxicology, vol. 34, no. 5, pp. 463–467, 1996.
[4]
S. Burgalassi, L. Panichi, M. F. Saettone, J. Jacobsen, and M. R. Rassing, “Development and in vitro/in vivo testing of mucoadhesive buccal patches releasing benzydamine and lidocaine,” International Journal of Pharmaceutics, vol. 133, no. 1-2, pp. 1–7, 1996.
[5]
D. Kulkarni, A. K. Dwivedi, J. P. S. Sarin, and S. Singh, “Tamarind seed polyose: a potential polysaccharide for sustained release of verapamil hydrochloride as a model drug,” Indian Journal of Pharmaceutical Sciences, vol. 59, no. 1, pp. 1–7, 1997.
[6]
M. F. Saettone, S. Burgalassi, B. Giannaccini, E. Boldrini, P. Bianchini, and G. Luciani, “Ophthalmic solutions viscosified with tamarind seed polysaccharide,” PCT International Application WO, vol. 97, no. 28, p. 787, 1997.
[7]
P. Goyal, V. Kumar, and P. Sharma, “Carboxymethylation of Tamarind kernel powder,” Carbohydrate Polymers, vol. 69, no. 2, pp. 251–255, 2007.
[8]
L. J. Scott and C. M. Perry, “Tramadol: a review of its use in perioperative pain,” Drugs, vol. 60, no. 1, pp. 139–176, 2000.
[9]
T. Salsa, F. Veiga, and M. E. Pina, “Oral controlled-release dosage forms. I. Cellulose ether polymers in hydrophilic matrices,” Drug Development and Industrial Pharmacy, vol. 23, no. 9, pp. 929–938, 1997.
[10]
J. Cooper and C. Gunn, “Powder flow and compaction,” in Tutorial Pharmacy, S. J. Carter, Ed., pp. 211–233, CBS Publishers, New Delhi, India, 1986.
[11]
D. Shah, Y. Shah, and R. Pradhan, “Development and evaluation of controlled-release diltiazem HCl microparticles using cross-linked poly(vinyl alcohol),” Drug Development and Industrial Pharmacy, vol. 23, no. 6, pp. 567–574, 1997.
[12]
M. E. Aulton and T. I. Wells, Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, London, UK, 1988.
[13]
Pharmacopoeia of India, Ministry of Health and Family Welfare, Government of India, New Delhi, India, 1996.
[14]
J. G. Wagner, “Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules,” Journal of Pharmaceutical Sciences, vol. 58, no. 10, pp. 1253–1257, 1969.
[15]
MatrixT, “Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices,” Journal of Pharmaceutical Sciences, vol. 52, pp. 1145–1149, 1963.
[16]
A. W. Hixon and J. H. Crowell, “Dependence of reaction velocity upon surface and agitation,” Industrial & Engineering Chemistry, vol. 23, pp. 923–931, 1931.
[17]
R. W. Korsmeyer, R. Gurny, and E. Doelker, “Mechanisms of solute release from porous hydrophilic polymers,” International Journal of Pharmaceutics, vol. 15, no. 1, pp. 25–35, 1983.
[18]
N. A. Peppas, “Analysis of Fickian and non-Fickian drug release from polymers,” Pharmaceutica Acta Helvetiae, vol. 60, no. 4, pp. 110–111, 1985.
[19]
M. Bamba, F. Puisieux, J. P. Marty, and J. T. Carstensen, “Release mechanisms in gelforming sustained release preparations,” International Journal of Pharmaceutics, vol. 2, no. 5-6, pp. 307–315, 1979.
[20]
S. Jain, S. K. Yadav, and U. K. Patil, “Preparation and evaluation of sustained release matrix tablet of furosemide using natural polymers,” Research Journal of Pharmacy and Technology, vol. 1, article 375, no. 4, 2008.
[21]
The European agency for the evaluation of medicinal products (EMEA), “Human medicines evaluation unit, note for guidance on quality of modified release products: oral dosage forms,” CPMP/QWP/96(I):604, 1999.
[22]
L. Lachman, H. Lieberman, and J. Kaning, The Theory and Practice of Industrial Pharmacy, Lei & Feiberger, Philadelphia, Pa, USA, 3rd edition, 1970.
[23]
R. B. Miller, S. T. A. Malkowska, W. Wimmer, et al., “A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient,” US Patent no. 6, 254, 887, 2001.
